Biogen Reports Real-World Experience with Aduhelm in Early Alzheimer's Disease

Biogen today presented real-world experience data from treatment centers using Aduhelm (aducanumab) in patients with early Alzheimer's disease. The data showed consistent amyloid plaque reduction across patients treated in clinical practice, with safety profiles consistent with clinical trial observations. The real-world data provide additional insights into the use of Aduhelm in routine clinical practice.